Physician profile
John E Marvel
NPI 1265432173
$1,683.02
in general payments reported to CMS, 2019-2025
36 companies · $85.97 in 2025
The $85.97 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $978 · 2020: $360 · 2021: $170 · 2022: $41.79 · 2023: $47.44 · 2025: $85.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $133.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $258.32 | 2019-2021 | |
| Amgen INC. | $131.54 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $130.23 | 2019-2025 | Libtayo |
| Varian Medical Systems, INC. | $107.50 | 2019 | |
| Merck Sharp & Dohme LLC | $86.75 | 2019-2020 | |
| Lilly USA, LLC | $80.24 | 2019-2020 | |
| Daiichi Sankyo INC. | $68.42 | 2019-2020 | |
| Janssen Biotech, INC. | $62.34 | 2019-2023 | Tremfya |
| Shire North American Group INC | $58.95 | 2019 | |
| Genentech USA, INC. | $58.01 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $52.69 | 2019 | |
| Biofrontera INC. | $44.95 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Pharmacyclics LLC, An Abbvie Company | $40.65 | 2020 | |
| Abbvie INC. | $39.95 | 2020-2021 | |
| Celgene Corporation | $38.37 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $36.25 | 2019 | |
| Azurity Pharmaceuticals, INC. | $29.82 | 2025 | Vivimusta |
| Bayer Healthcare Pharmaceuticals INC. | $29.28 | 2019 | |
| Jazz Pharmaceuticals INC. | $28.11 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $27.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.46 | 2020-2021 | |
| Puma Biotechnology, INC. | $24.17 | 2019 | |
| Tersera Therapeutics LLC | $20.48 | 2021 | |
| Dusa Pharmaceuticals, INC. | $19.39 | 2019 | |
| Leo Pharma INC. | $19.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.24 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.03 | 2025 | Ultomiris |
| Mylan Institutional INC. | $17.33 | 2019 | |
| Dova Pharmaceuticals | $16.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.25 | 2019 | |
| Glaxosmithkline, LLC. | $14.93 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.32 | 2019 | |
| Beigene USA, INC. | $13.31 | 2020 | |
| Eisai INC. | $13.11 | 2020 | |
| Emd Serono, INC. | $10.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Marvel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.